GSK is a global biopharma company focused on infectious diseases, HIV, respiratory, immunology, and oncology, operating through its vaccines business and specialty medicines including its ViiV Healthcare HIV joint venture.
Primary: Independent Review Committee (IRC)-assessed progression-free survival (PFS) — Median PFS was 5.5 months with Ris-Rez versus 1.4 months with chemotherapy (HR, 0.33; 95% CI, 0.20-0.55; p<0.0001), after a median follow-up of 7.1 months
· Ris-Rez reduced the risk of disease progression or death by 67% compared with chemotherapy
· Grade 3 or higher treatment-related adverse events occurred in 93% of patients receiving Ris-Rez at the 12 mg/kg dose and 83% in those receiving chemotherapy
· Treatment-related adverse events led to discontinuation in 4% of patients receiving Ris-Rez and 2% of patients receiving chemotherapy
· Ris-Rez 12.0 mg/kg every 3 weeks versus gemcitabine 1,000 mg/m2 on days 1 and 8 plus docetaxel 75 mg/m2 on day 8 every 3 weeks
· The late-breaking results were presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and will support a regulatory submission by Hansoh in China
Safety: Grade 3 or higher treatment-related adverse events in 93% on Ris-Rez versus 83% on chemotherapy, the most common being haematologic events; discontinuations due to treatment-related adverse events 4% versus 2%; safety findings consistent with prior findings in this tumour type
Primary: Confirmed objective response rate (ORR) in the Phase Ib dose-optimisation portion of EMBOLD PanTumour-101 (NCT06551142) in relapsed extensive-stage small cell lung cancer — Confirmed ORR of 61% at the 8 mg/kg dose (n=11/18; 95% CI: 35.7-82.7), compared with 32% at the 6 mg/kg dose (n=7/22; 95% CI: 13.9-54.9)
· 50 ES-SCLC patients who had received a median of two prior therapies
· Median follow-up of 100.5 days
· Data supported selection of the 8 mg/kg dose being evaluated in the global phase III EMBOLD SCLC-301 study
Safety: Manageable across both dose levels: grade 3 or higher treatment-related adverse events in 42% of patients at 8 mg/kg and 15% at 6 mg/kg, most commonly haematological; interstitial lung disease in 1 out of 50 patients (2%, grade 2)
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Approved US Oct 2025 (EU, Japan) in combination after two or more prior lines; in other markets after one or more prior lines. Only anti-BCMA ADC accessible in community settings.
Nucala
Approved · ActiveModality: biologic
Target IL-5
Indications
Severe eosinophilic asthma(Approved)
Eosinophilic granulomatosis with polyangiitis (EGPA)(Approved)
Hypereosinophilic syndrome(Approved)
Chronic rhinosinusitis with nasal polyps(Approved)
Status note Named among five key assets with major approvals in 2025; indication not stated in excerpts.
Blujepa
Approved · ActiveModality: small molecule
Target bacterial type II topoisomerase
Indications
Uncomplicated urinary tract infection(Approved)
Status note Named among five key assets with major approvals in 2025; indication not stated in excerpts.
Status note Phase 2 registrational AZUR-1 in curative-intent dMMR/MSI-H rectal cancer (Breakthrough + Fast Track + National Priority Voucher). AZUR-2 in colon cancer ongoing.
Status note Pivotal Phase 3 data reported; next-generation low-carbon propellant formulation.
Risvutatug rezetecan
Phase 3 · Active
Target B7-H3
Indications
Extensive-stage small cell lung cancer (2L/3L)(Phase 3)
Status note Pivotal trial started in 2L/3L ES-SCLC.
Efimosfermin
Phase 3 · Active
Target FGF21
Indications
MASH-related fibrosis(Phase 3)
Status note Pivotal trial started for fibrosis caused by MASH.
Arexvy
Approved · ActiveModality: vaccine
Indications
RSV(Approved)
Status note Expanded approvals in 2025.
Shingrix
Approved · ActiveModality: vaccine
Indications
Shingles(Approved)
Status note Expanded approvals in 2025.
Per-asset detail extracted from the 20-F filed 2026-03-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (163 as sponsor, 124 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.